Biotin - MedDay Pharmaceuticals

Drug Profile

Biotin - MedDay Pharmaceuticals

Alternative Names: Coenzyme R; D-biotin; MD 1003; Qizenday; Vitamin H

Latest Information Update: 19 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedDay Pharmaceuticals
  • Class Coenzymes; Imidazoles; Small molecules; Vitamins
  • Mechanism of Action Enzyme modulators; Enzyme stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II/III Adrenomyeloneuropathy
  • Phase II Amyotrophic lateral sclerosis
  • Phase I/II Charcot-Marie-Tooth disease; Chronic inflammatory demyelinating polyradiculoneuropathy
  • Preclinical Adrenoleucodystrophy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 27 Nov 2017 Biotine is available on a Named Patient Access Programme in some European countries including France
  • 13 Nov 2017 Regulatory submission withdrawn for Multiple sclerosis in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top